OncLive TV

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.

Hui-Zi Chen, MD, PhD, discusses how the IMpower133 trial has helped to propel the field of small-cell lung cancer forward.

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses how to judiciously use steroids to manage adverse events in patients with melanoma who are receiving immunotherapy.

Alvin H. Schmaier, MD, discusses managing thrombosis in patients with hematologic malignancies.

Jerald P. Radich, MD, discusses the utility of minimal residual disease in hematologic malignancies.

Sagar Lonial, MD, FACP, discusses the role of targeted therapy in acute myeloid leukemia and acute lymphoblastic leukemia.

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the results of the phase III RADICALS-RT trial in prostate cancer.

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

Emmanuel S. Antonarakis, MBBCh, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

Srikanth Nagalla, MD, discusses research efforts dedicated to the development of timely assays for direct oral anticoagulants in myeloproliferative neoplasms.

Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.

John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses the ongoing phase Ib First-MIND trial in diffuse large B-cell lymphoma (DLBCL).

Vip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.

Stephen J. Schuster, MD, director of the Lymphoma Program, director of Translational Research, Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clincai Care and Research at University of Pennsylvania, discusses the results of the phase I/Ib dose-escalation GO29781 trial (NCT02500407) with mosunetuzumab in relapsed/refractory non-Hodgkin lymphoma (NHL).

Kathleen Moore, MD, discusses the safety profile of mirvetuximab soravtansine, an antibody-drug conjugate that targets the FRα transmembrane protein, in ovarian cancer.

Rana R. McKay, MD, discusses the rationale for conducting a real-world analysis of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.

Leonard G. Gomella, MD, discusses recommendations for screening in prostate cancer.

Scott T. Tagawa, MD, MS, discusses the safety profile of novel monoclonal antibody 225Ac-J591 in metastatic castration-resistant prostate cancer.

Petros Grivas, MD, PhD, discusses the role of targeted therapy in prostate cancer.

Srikanth Nagalla, MD, discusses aspirin recommendations for patients with myeloproliferative neoplasms who are receiving direct oral anticoagulants.

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

Ritu Salani, MD, provides insight into how to approach selection of chemotherapy in ovarian cancer.